TY - JOUR
T1 - Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling
AU - Salah, Husam M.
AU - Verma, Subodh
AU - Santos-Gallego, Carlos G.
AU - Bhatt, Ankeet S.
AU - Vaduganathan, Muthiah
AU - Khan, Muhammad Shahzeb
AU - Lopes, Renato D.
AU - Al’Aref, Subhi J.
AU - McGuire, Darren K.
AU - Fudim, Marat
N1 - Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/10
Y1 - 2022/10
N2 - Sodium-glucose cotransporter 2 (SGLT2) inhibitors have evident cardiovascular benefits in patients with type 2 diabetes with or at high risk for atherosclerotic cardiovascular disease, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction (only empagliflozin and dapagliflozin have been investigated in this group so far), and chronic kidney disease. Prevention and reversal of adverse cardiac remodeling is one of the mechanisms by which SGLT2 inhibitors may exert cardiovascular benefits, especially heart failure-related outcomes. Cardiac remodeling encompasses molecular, cellular, and interstitial changes that result in favorable changes in the mass, geometry, size, and function of the heart. The pathophysiological mechanisms of adverse cardiac remodeling are related to increased apoptosis and necrosis, decreased autophagy, impairments of myocardial oxygen supply and demand, and altered energy metabolism. Herein, the accumulating evidence from animal and human studies is reviewed investigating the effects of SGLT2 inhibitors on these mechanisms of cardiac remodeling.
AB - Sodium-glucose cotransporter 2 (SGLT2) inhibitors have evident cardiovascular benefits in patients with type 2 diabetes with or at high risk for atherosclerotic cardiovascular disease, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction (only empagliflozin and dapagliflozin have been investigated in this group so far), and chronic kidney disease. Prevention and reversal of adverse cardiac remodeling is one of the mechanisms by which SGLT2 inhibitors may exert cardiovascular benefits, especially heart failure-related outcomes. Cardiac remodeling encompasses molecular, cellular, and interstitial changes that result in favorable changes in the mass, geometry, size, and function of the heart. The pathophysiological mechanisms of adverse cardiac remodeling are related to increased apoptosis and necrosis, decreased autophagy, impairments of myocardial oxygen supply and demand, and altered energy metabolism. Herein, the accumulating evidence from animal and human studies is reviewed investigating the effects of SGLT2 inhibitors on these mechanisms of cardiac remodeling.
KW - Cardiac remodeling
KW - HFpEF
KW - HFrEF
KW - Heart failure
KW - Mechanisms
KW - SGLT2 inhibitors
KW - SGLT2i
UR - http://www.scopus.com/inward/record.url?scp=85126311811&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126311811&partnerID=8YFLogxK
U2 - 10.1007/s12265-022-10220-5
DO - 10.1007/s12265-022-10220-5
M3 - Review article
C2 - 35290593
AN - SCOPUS:85126311811
SN - 1937-5387
VL - 15
SP - 944
EP - 956
JO - Journal of cardiovascular translational research
JF - Journal of cardiovascular translational research
IS - 5
ER -